Paediatrics (RCH) - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/199

Filters

2011 3
Reset filters

Settings
Statistics
Citations
Author: Licciardi, Paul × Author: Mulholland, Edward × End date: 2011 × Start date: 2011 × Type: Journal Article ×

Search Results

Now showing 1 - 3 of 3
  • Item
    Thumbnail Image
    Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
    Russell, FM ; Balloch, A ; Licciardi, PV ; Carapetis, JR ; Tikoduadua, L ; Waqatakirewa, L ; Cheung, YB ; Mulholland, EK ; Tang, MLK (ELSEVIER SCI LTD, 2011-06-15)
    AIM: To evaluate whether the avidity of serotype-specific IgG to pneumococcal serotypes is enhanced by an increased number of doses of the 7-valent pneumococcal conjugate vaccine (PCV) in infancy or by a 12 month 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster, and/or subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months. METHODS: Fijian infants aged 6 weeks were recruited, stratified by ethnicity and randomized to 8 groups to receive 0, 1, 2, or 3 doses of PCV, with or without 23vPPS at 12 months. All children received mPPS at 17 months of age. Avidity of serotype-specific IgG for PCV serotypes in the first 12 months and for all 23vPPS serotypes thereafter was assessed by EIA after sodium thiocyanate elution. RESULTS: At one month post primary series, the 2 and 3 PCV dose groups demonstrated similar avidity, with the single dose group tending to have lower avidity. However, by age 9 months, the single dose group had similar avidity to the 2 and 3 PCV groups for most serotypes. The 23vPPS booster enhanced affinity maturation for most serotypes and this was most marked in those groups that received a single PCV dose. There was little further increase following the mPPS. CONCLUSIONS: By 9 months of age, similar avidity can be induced following one, 2 or 3 doses of PCV. A 23vPPS booster at 12 months enhanced affinity maturation with an increase in antibody avidity for most serotypes. Subsequent re-challenge with mPPS at 17 months did not further enhance the avidity of serotype-specific response in the 12 month 23vPPS groups.
  • Item
    Thumbnail Image
    Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age
    Russell, FM ; Carapetis, JR ; Burton, RL ; Lin, J ; Licciardi, PV ; Balloch, A ; Tikoduadua, L ; Waqatakirewa, L ; Cheung, YB ; Tang, MLK ; Nahm, MH ; Mulholland, EK (ELSEVIER SCI LTD, 2011-01-10)
    Opsonophagocytic activity (OPA) was measured following reduced infant doses of 7-valent pneumococcal conjugate vaccine (PCV-7) with or without 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months, and subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months. Fijian infants were randomized to receive 0, 1, 2, or 3 PCV-7 doses. Half received PPV-23 at 12 months and all received mPPS at 17 months. OPA was performed on up to 14 serotypes. Three and 2 PCV-7 doses resulted in similar OPA for most PCV-7 serotypes up to 9 months and for half of the serotypes at 12 months. A single dose improved OPA compared with the unvaccinated group. PPV-23 significantly improved OPA for all serotypes tested but in general, was associated with diminished responses following re-challenge.
  • Item
    Thumbnail Image
    Age-and serotype-dependent antibody response to pneumococcal polysaccharides Reply
    Balloch, A ; Licciardi, PV ; Russell, FM ; Mulholland, EK ; Tang, MLK (MOSBY-ELSEVIER, 2011-04)